203 related articles for article (PubMed ID: 33028363)
1. To what extent do supervised drug consumption services incorporate non-injection routes of administration? A systematic scoping review documenting existing facilities.
Speed KA; Gehring ND; Launier K; O'Brien D; Campbell S; Hyshka E
Harm Reduct J; 2020 Oct; 17(1):72. PubMed ID: 33028363
[TBL] [Abstract][Full Text] [Related]
2. The state of science on including inhalation within supervised consumption services: A scoping review of academic and grey literature.
Gehring ND; Speed KA; Launier K; O'Brien D; Campbell S; Hyshka E
Int J Drug Policy; 2022 Apr; 102():103589. PubMed ID: 35101668
[TBL] [Abstract][Full Text] [Related]
3. Supervised inhalation is an important part of supervised consumption services.
Bourque S; Pijl EM; Mason E; Manning J; Motz T
Can J Public Health; 2019 Apr; 110(2):210-215. PubMed ID: 30725386
[TBL] [Abstract][Full Text] [Related]
4. Peer-assisted injection as a harm reduction measure in a supervised consumption service: a qualitative study of client experiences.
Pijl E; Oosterbroek T; Motz T; Mason E; Hamilton K
Harm Reduct J; 2021 Jan; 18(1):5. PubMed ID: 33407575
[TBL] [Abstract][Full Text] [Related]
5. Hoots and harm reduction: a qualitative study identifying gaps in overdose prevention among women who smoke drugs.
Bardwell G; Austin T; Maher L; Boyd J
Harm Reduct J; 2021 Mar; 18(1):29. PubMed ID: 33678163
[TBL] [Abstract][Full Text] [Related]
6. Supervised Inhalation Sites: Preventing Overdose and Reducing Health Inequities among People Who Use Drugs.
Lu A; Kim C; Rosen JG; Thompson E; Tardif J; Welwean R; Park JN
Subst Use Misuse; 2024; 59(4):520-526. PubMed ID: 38044494
[TBL] [Abstract][Full Text] [Related]
7. Supervised injection services: what has been demonstrated? A systematic literature review.
Potier C; Laprévote V; Dubois-Arber F; Cottencin O; Rolland B
Drug Alcohol Depend; 2014 Dec; 145():48-68. PubMed ID: 25456324
[TBL] [Abstract][Full Text] [Related]
8. "You don't have to squirrel away in a staircase": Patient motivations for attending a novel supervised drug consumption service in acute care.
Kosteniuk B; Salvalaggio G; McNeil R; Brooks HL; Dong K; Twan S; Brouwer J; Hyshka E
Int J Drug Policy; 2021 Oct; 96():103275. PubMed ID: 34020865
[TBL] [Abstract][Full Text] [Related]
9. A scoping review of qualitative research on barriers and facilitators to the use of supervised consumption services.
Ivsins A; Warnock A; Small W; Strike C; Kerr T; Bardwell G
Int J Drug Policy; 2023 Jan; 111():103910. PubMed ID: 36436364
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
[TBL] [Abstract][Full Text] [Related]
12. Opening Canada's first Health Canada-approved supervised consumption sites.
Patterson T; Bharmal A; Padhi S; Buchner C; Gibson E; Lee V
Can J Public Health; 2018 Aug; 109(4):581-584. PubMed ID: 30039262
[TBL] [Abstract][Full Text] [Related]
13. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
14. Operating an overdose prevention site within a temporary emergency shelter during the COVID-19 pandemic.
Galarneau LR; Speed K; Taylor M; Hyshka E
Can J Public Health; 2023 Oct; 114(5):787-795. PubMed ID: 37462841
[TBL] [Abstract][Full Text] [Related]
15. Acceptability of safe drug consumption spaces among people who inject drugs in rural West Virginia.
O'Rourke A; White RH; Park JN; Rodriguez K; Kilkenny ME; Sherman SG; Allen ST
Harm Reduct J; 2019 Aug; 16(1):51. PubMed ID: 31470864
[TBL] [Abstract][Full Text] [Related]
16. Difficulty accessing supervised consumption services during the COVID-19 pandemic among people who use drugs in Vancouver, Canada.
Cassie R; Hayashi K; DeBeck K; Milloy MJ; Cui Z; Strike C; West J; Kennedy MC
Harm Reduct J; 2022 Nov; 19(1):126. PubMed ID: 36401299
[TBL] [Abstract][Full Text] [Related]
17. Mobilizing Drug Consumption Rooms: inter-place networks and harm reduction drug policy.
McCann E; Temenos C
Health Place; 2015 Jan; 31():216-23. PubMed ID: 25576837
[TBL] [Abstract][Full Text] [Related]
18. Rules and Eligibility Criteria for Supervised Consumption Services Feasibility Studies - A Scoping Review.
Xavier J; Rudzinski K; Guta A; Carusone SC; Strike C
Int J Drug Policy; 2021 Feb; 88():103040. PubMed ID: 33220597
[TBL] [Abstract][Full Text] [Related]
19. Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia.
Roxburgh A; Jauncey M; Day C; Bartlett M; Cogger S; Dietze P; Nielsen S; Latimer J; Clark N
Harm Reduct J; 2021 Feb; 18(1):20. PubMed ID: 33596940
[TBL] [Abstract][Full Text] [Related]
20. Mobile supervised consumption services in Rural British Columbia: lessons learned.
Mema SC; Frosst G; Bridgeman J; Drake H; Dolman C; Lappalainen L; Corneil T
Harm Reduct J; 2019 Jan; 16(1):4. PubMed ID: 30634986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
